Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Quiz|Articles|May 22, 2026
OncLive Weekly News Quiz (5/22/2026): Test Your Knowledge on Updates in Bladder Cancer, NSCLC, and AML
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Key Takeaways
- ”, no repetitive openers, each ending with a period).
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
A supplemental biologics license application for nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG is supported in part by findings from Cohort B of the phase 2/3 QUILT-3.032 trial (NCT03022825). What 12-month disease-free survival (DFS) rate was reported among patients with high-grade, papillary-only non–muscle-invasive bladder cancer (NMIBC)?
Advertisement
Related to this article
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.
A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.
The FDA set a target action date of June 29, 2027, for bezuclastinib's NDA in advanced systemic mastocytosis, backed by APEX trial data.
The top 5 OncLive TV videos of the week cover insights in polycythemia vera, myelodysplastic syndrome, myelofibrosis, and acute myeloid leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
3
Dr Kuykendall on the Significance of the FDA Approval of Rusfertide for Polycythemia Vera
4